Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer(CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in Colorectal Cancer Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal) Mark is Queen's Lead of the Health Data Research UK Substantive Site, one of only 6 in the UK, which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for Cancer Strategy for HDR-UK. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH), an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (published in Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut etc). He is co-lead of an ambitious proposal to develop a Global Innovation Institute in Belfast which will include the One Health Innovation Centre (OHIC), the world’s first Health and Agri-Food Informatics Innovation Centre. Mark’s work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research. He is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including the European Alliance for Personalised Medicine, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark’s advocacy work was instrumental in the recent decision to include boys in national UK HPV vaccination programmes. He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries.
Ty S. Schepis, Ph.D., is an associate professor of psychology at Texas State University. He obtained his Ph.D. in clinical psychology from the University of Texas Southwestern Medical Center, and he completed a National Institutes of Health-funded Postdoctoral Fellowship in Substance Abuse at Yale School of Medicine. His primary expertise is in prescription medication misuse and nicotine use across the lifespan, and his work has been published in notable academic journals, including Addiction, Journal of Consulting and Clinical Psychology, Journal of the American Academy of Child and Adolescent Psychiatry, and PAIN. He has been a principal investigator on four funded National Institutes of Health research grants, all from the National Institute on Drug Abuse, with over $1 million in total research funding.
Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001. In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer. Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.